Investor Home

Webcast ImageWebcast
Cerecor, Inc at Rodman & Renshaw 18th Annual Global Investment Conference (Live)
09/12/16 at 2:35 p.m. ET
Cerecor, Inc at Rodman & Renshaw 18th Annual Global Investment Conference
Monday, September 12, 2016 2:35 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Cerecor Inc. is a clinical stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric diseases by addressing the unmet medical needs of underserved patient segments. We are committed to the development of drugs that improve lives by applying our extensive knowledge and experience in central nervous system disorders....more

Recent Newsmore 
08/22/16
Cerecor to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
BALTIMORE--(BUSINESS WIRE)--Aug. 22, 2016-- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016,... 
08/15/16
Cerecor Inc. Reports Second Quarter 2016 Financial Results
BALTIMORE--(BUSINESS WIRE)--Aug. 15, 2016-- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates to make a difference in the lives of patients with neurological and psychiatric disorders, today announced its financial results for the second quarter ended June 30, 2016. “We are excited about both of our Phase 2 programs and are encouraged by the scientific community’s increasing interest in ... 
07/25/16
Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder
BALTIMORE--(BUSINESS WIRE)--Jul. 25, 2016-- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that the Pharmacotherapies for Alcohol and Substance Use Disorders (PASA) Consortium has provided a grant to Dr. Colin Haile (Principal Investigator, University of Houston), Dr. Therese Kosten (Co-Investiga... 
Upcoming Eventsmore 
DateTitleRemind
Me
Prior to
Event
09/12/16 2:35 p.m. ET
Cerecor, Inc at Rodman & Renshaw 18th Annual Global Investment Conference
days
Enter your e-mail address 
IR Contact

E-mail: ir@cerecor.com

Stock Quotemore 
Exchange :NASDAQ CM (US Dollar)
Price :$4.10
Change : Stock is Up 0.09 (2.24%)
Volume :39,900
Data as of 08/26/16 3:17 p.m. ET
Minimum 15 minute delay
Request Information
 
Obtain investor relations information by contacting us.
 
More
E-mail Alerts
Sign up to receive e-mail alerts whenever Cerecor, Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.